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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on selenium-enriched biomass of Yarrowia
lipolytica as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is the dried and heat-
killed selenium-enriched biomass of Y. lipolytica. This yeast species is widespread in nature, can be
found in the environment and in foods, and was attributed the qualiﬁed presumption of safety (QPS)
status for production purposes in 2018, including food and feed products based on biomass of the
yeast. The production process, fermentation in the presence of sodium selenite, includes a heat-killing
step of the yeast, resulting in the absence of viable Y. lipolytica in the NF. The maximum total selenium
content in the NF is 200 lg Se/g, mainly present as organic selenium compounds. The applicant
proposed to use the NF as a food supplement. The target population proposed by the applicant is the
general population from 3 years of age onwards, with maximum proposed use levels of 0.2 g/day for
children from 3 to 9 years of age and 1 g/day thereafter. The Panel considers that the yeast biomass
is not of safety concern at the proposed use levels. The Panel also considers that the selenium
provided by the NF is as safe as selenium from other dietary sources. However, the Panel notes that,
at the use levels proposed by the applicant, the intake of the NF could, in combination with a
background diet high in selenium, lead to total selenium intakes exceeding the UL for selenium in all
target population groups, except for children from 7 to 9 years. Furthermore, the Panel considers that
newly emerging data warrant a reassessment of the UL for selenium.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 22 August 2018, Skotan S.A. submitted a request to the European Commission in accordance
with Article 10 of Regulation (EU) No 2015/22831 to place selenium-enriched biomass from Yarrowia
lipolytica on the Union market as a novel food (NF).
Selenium-enriched biomass from Yarrowia lipolytica is proposed for use in various foods, including
food for special medical purposes, food supplements and total diet replacement foods for weight control.
The target population is the general population, from 3 years of age onwards.
On 18 February 2019, and in accordance with Article 10(3) of Regulation (EU) 2015/2283, the
European Commission asked the European Food Safety Authority (EFSA) to provide a scientiﬁc opinion
on selenium-enriched biomass from Yarrowia lipolytica as a NF.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following an EFSA request for supplementary information.
Administrative and scientiﬁc requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469.2
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of NF applications.3 As indicated in this guidance, it is
the duty of the applicant to provide all the available (proprietary, conﬁdential and published) scientiﬁc
data, including both data in favour and not in favour to supporting the safety of the proposed NF.
This NF application does not include a request for the protection of proprietary data.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA
NDA Panel, 2016) and the principles described in the relevant existing guidance documents from the
EFSA Scientiﬁc Committee. The legal provisions for the assessment are laid down in Article 11 of
Regulation (EU) 2015/2283 and in Article 7 of Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use and is not an assessment of the efﬁcacy of the NF with regard to any
(claimed) beneﬁt.
3. Assessment
3.1. Introduction
The NF which is the subject of the application is the selenium-enriched biomass of the yeast Y.
lipolytica.
The NF falls under category (ii), i.e. food consisting of, isolated from or produced from
microorganisms, fungi or algae, according to Article 3(2)(a) of Regulation (EU) No 2015/2283.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientiﬁc
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva
K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M, Salminen S,
Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal
2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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The NF is produced by fermentation, using commonly used nutrient sources plus sodium selenite.
The NF is proposed to be used in food supplements. The target population proposed by the applicant
is the general population from 3 years of age onwards.
3.2. Identity of the NF
The NF is the selenium-enriched biomass of the yeast Y. lipolytica.
The taxonomic position of the species was ﬁrst established by Van der Walt and von Arx (1980),
with the following microbiological taxonomy. Kingdom: fungi; subkingdom: Dikaryota; division:
Ascomycota; subdivision: Saccharomycotina; class: Saccharomycetes; order: Saccharomycetales;
family: Dipodascaceae; genus: Yarrowia; species: Yarrowia lipolytica.
The species Y. lipolytica can be found in the ‘IndexFungorum’ database4 (record number
ID108643).
In 2018, the EFSA BIOHAZ Panel assessed the yeast, i.e. Y. lipolytica, that is used to produce the
NF, and recommended this yeast for the qualiﬁed presumption of safety (QPS) status but only for
production purposes, including food and feed products based on biomass (EFSA BIOHAZ Panel, 2018).
The qualiﬁcation ‘only for production purposes’ requires that there are no viable Y. lipolytica cells in the
ﬁnal product.
The Panel has previously favourably assessed the safety of Y. lipolytica yeast biomass as a novel
food (EFSA NDA Panel, 2019).
3.3. Production process
According to the information provided, the NF is produced following Good Manufacturing Practice
(GMP) and Hazard Analysis Critical Control Points (HACCP) principles.
Flow charts of the manufacturing process and detailed information on the culture conditions and
media have been provided (conﬁdential).
The ﬁrst step of the manufacturing process consists of the preparation of the Y. lipolytica yeast
inoculum. Proliferation of the yeast is continued in tanks of increasing capacity using culture media
consisting of nutrient sources (conﬁdential) commonly employed in fermentation processes. The
culture conditions (i.e. temperature, aeration, pH, speed of mixing) are continuously monitored.
The main fermentation step is carried out for about 10 hours in the presence of sodium selenite
(Na2SeO3), which is among the mineral substances authorised to be added to foods (including food
supplements).5
After reaching a certain concentration of yeast dry matter, the selenium-enriched yeast is
harvested, i.e. centrifuged, rinsed with water, and centrifuged again in order to remove remnant
culture medium. Thereafter the yeast biomass is dried in a drum drier at a temperature of > 160°C
until a moisture content of less than 5% is achieved. During this step, the yeast cells are killed.
As noted in the previous safety assessment of Y. lipolytica biomass (EFSA NDA Panel, 2019), the
Panel reiterates that in order to monitor the efﬁciency of the heat treatment and to guarantee that
there are no viable Y. lipolytica cells remaining in the dried biomass, testing for the presence of viable
yeast cells has to be carried out immediately after the heat treatment (see also Speciﬁcations,
Table 4).
The Panel also notes that it has to be ensured that no cross-contamination occurs with viable
Y. lipolytica in the ﬁnal steps of the manufacturing process (packaging and storage).
The Panel considers that the production process is sufﬁciently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided batch-to-batch analysis for ﬁve batches of the NF (at a production scale
of ≥ 1000 L, with sodium selenite as the source for selenium) for total selenium content, selenium
speciation, proximate analysis and microbial counts (Table 1).
4 http://www.indexfungorum.org/names/names.asp
5 Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European Parliament
and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards the lists of vitamin
and minerals and their forms that can be added to foods, including food supplements, OJ L 314, 1.12.2009, p. 36–42.
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The Panel notes the consistent results of the batch-to-batch testing of the NF showing an average
content of total selenium of 175 lg Se/g with a SD of 4 lg Se/g. On average, 68% of this total
selenium is Se-methionine (range 67–69%), and 10% is Se-cysteine (range 10–11%).
Nutritional analyses were provided for two additional batches of the NF.
Information was submitted on the accreditation of the laboratories that conducted the analyses
presented in the application.
The Panel considers that the information provided on the composition of the NF is sufﬁcient and
does not raise safety concerns.
3.4.1. Stability
In order to demonstrate the stability of the NF, the applicant submitted results of stability testing
performed for 12 months at ambient conditions (20°C and 40–60% relative humidity (RH)) (Table 2).
Four batches of the NF were analysed. The parameters investigated were the content of total
selenium, water, protein, fat, total aerobic microbial count (TAMC), total yeast and mould count
(TYMC), coliforms and Salmonella. Salmonella and Coliforms were not detected (i.e. absent in 25 g
and 1 g, respectively) in any sample over the testing period. Protein and fat contents decreased
slightly over time. Results for total selenium content, TAMC, TYMC and water content are shown in
Table 2.
Table 1: Batch-to-batch analysis of the NF
Parameter (unit)
Batch number
S01-19 S02-19 S03-19 S04-19 S05-19
Total selenium (lg/g) 179 176 177 174 168
Se-methionine (lg/g)(1) 124 121 120 117 112
Se-cysteine (lg/g)(1) 20 18 18 18 17
Protein (%) 43.7 43.9 44.3 43.9 44.3
Dietary ﬁbre (%) 31.7 31.5 31.7 31.0 29.9
Sugars (%) < 0.2 < 0.2 < 0.2 < 0.2 < 0.2
Fat (%) 11.8 11.6 11.6 11.7 11.6
Dry matter (%) 96.6 96.8 96.9 96.9 96.8
Water (%) 3.4 3.2 3.1 3.1 3.2
Ash (%) 9.5 9.7 9.8 9.7 9.7
Contaminants
Cadmium (mg/kg) 0.026 0.028 0.027 0.026 0.027
Mercury (mg/kg) 0.015 0.016 0.016 0.016 0.016
Lead (mg/kg) 0.044 0.044 0.045 0.042 0.043
Microbials
TAMC (CFU/g) 6.5 9 103 1.9 9 103 3.5 9 103 5.5 9 103 1.4 9 103
TYMC (CFU/g) < 10 < 10 < 10 < 10 < 10
Number of coliforms (CFU/g) < 10 < 10 < 10 < 10 < 10
Salmonella spp. (in 25 g) Not detected Not detected Not detected Not detected Not detected
TAMC: total aerobic microbial count, TYMC: total yeast and mould count, CFU: colony forming units, Se: selenium.
(1): Se-methionine and Se-cysteine as selenium.
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In addition, the applicant provided stability tests with one batch (Nr. SAJ44) of the NF with testing
performed at standard storage conditions (30°C and at 65% RH) and at accelerated conditions (40°C
and at 75% RH) up to 6 months (Table 3). The batch of the NF was analysed for its content of
selenium, water, protein, B-group vitamins (thiamine, riboﬂavin, biotin, folic acid, vitamins B6 and B12;
not shown) and for microbial counts.
Given the absence of relevant changes in the composition of the NF under ambient conditions for
up to 12 months and accelerated storage conditions for up to 6 months, the applicant proposed a
shelf-life of 12 months for the NF.
The Panel notes that the batches analysed for the stability testing contained higher selenium
concentrations than set out in the speciﬁcations for the NF. However, since the selenium is not
Table 2: Stability testing at ambient conditions for selenium (lg/g), TAMC (CFU/g), TYMC (CFU/g)
and water content (in %)
Batch # Param.
Time (in months)
1 2 3 4 5 6 7 8 9 10 11 12
SAJ45 Selenium 248 247 247 247 245 245 244 244 243 242 241 239
TAMC 110 80 72 50 22 < 10 < 10 < 10 < 10 < 10 < 10 < 10
TYMC 30 18 12 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
Water 3.7 3.9 3.6 3.3 2.9 2.8 2.6 2.7 2.5 2.3 2.1 2.2
SAK51 Selenium 231 230 230 230 229 229 228 228 227 226 226 226
TAMC 80 75 72 60 48 33 22 10 < 10 < 10 < 10 < 10
TYMC 20 15 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
Water 3.0 3.1 3.4 2.9 2.7 2.4 2.1 1.8 1.3 1.4 1.2 1.1
SAK52 Selenium 254 250 253 252 251 251 249 249 248 247 245 244
TAMC 40 32 20 15 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
TYMC 10 12 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
Water 2.2 2.0 2.1 2.1 2.0 1.8 1.7 1.8 1.9 1.9 1.7 1.8
SAK53 Selenium 223 224 223 221 220 219 217 216 216 214 213 212
TAMC 130 110 100 110 75 62 50 37 24 10 < 10 < 10
TYMC 60 52 40 32 15 10 < 10 < 10 < 10 < 10 < 10 < 10
Water 4.7 4.7 4.8 4.7 4.5 4.5 4.4 4.2 4.0 3.9 3.6 3.2
TAMC: total aerobic microbial count, TYMC: total yeast and mould count, CFU: colony forming units.
The numbers of the microbial counts have to be multiplied by 10 in order to account for the dilution factor.
Table 3: Stability testing at standard storage conditions and at accelerated (Acc.) conditions for one
batch (#SAJ44)
Parameter 0 months
3 months 6 months
Standard Acc. Standard Acc.
Selenium (lg/g) 219.4 213.6 249.1 217.7 221.5
Water (%) 2.8 1.4 1.6 1.0 0.9
Protein (%) 42.82 43.15 43.33 45.60 43.15
TAMC (CFU/g) < 10 – – < 10 < 10
TYMC (CFU/g) < 10 – – < 10 < 10
S. aureus (in 1 g) Absent – – Absent Absent
E. coli (in 1 g) Absent – – Absent Absent
Salmonella spp. (in 10 g) Absent – – Absent Absent
Pseudomonas aeruginosa (in 1 g) Absent – – Absent Absent
Bile-tolerant Gram-negative bacteria (in 1 g,
qualitative test)
Absent – – Absent Absent
Bile-tolerant Gram-negative bacteria (in 1 g,
quantitative test)
< 10 – – < 10 < 10
TAMC: total aerobic microbial count; TYMC: total yeast and mould count; CFU: colony forming units.
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expected to have a major inﬂuence on the stability, the Panel considers that the data provided
sufﬁcient information with respect to the stability of the NF during 12 months.
3.5. Speciﬁcations
The speciﬁcations of the NF are indicated in Table 4.
The Panel considers that the information provided on the speciﬁcations of the NF is sufﬁcient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
There is no history of consumption of the NF.
The yeast, i.e. Y. lipolytica, which is used to produce the NF, is widespread in nature and can
naturally be found in foods high in fat and protein (e.g. cured meat, dairy products, various types of
cheese).
In 2019, the EFSA NDA Panel favourably assessed the safety of Y. lipolytica yeast biomass as a
novel food (EFSA NDA Panel, 2019).
Also in 2019, Y. lipolytica heat-killed yeast biomass was authorised for the placing on the market in/
as food supplements, excluding food supplements for infants and young children (Commission
Implementing Regulation (EU) 2019/7666).
Table 4: Speciﬁcations of the NF
Parameter Amount Method
Total selenium 165–200 lg/g PN-EN ISO 17294-2:2006
Se-methionine(1) 100–140 lg/g HPLC – ICP MS
Protein 40–50 g/100 g PN-A-79005-7:1997 orPN-EN ISO 8968-1:2014-03
Dietary ﬁbre 24–32 g/100 g AOAC 985.29 orPN-A-79011-15:1998
Sugars < 1.0 g/100 g PN-A-74252:1998
Fat 6.0–12.0 g/100 g AOAC 922.06 orPN-ISO 1444:2000
Total ash ≤ 15% PN-ISO 928:1999
Water ≤ 5% PN-EN ISO 665:2004
Dry matter ≥ 95% PN-EN ISO 665:2004
Heavy metals
Lead ≤ 3.0 mg/kg PN-EN ISO 17294-2:2006
Cadmium ≤ 1.0 mg/kg PN-EN ISO 17294-2:2006
Mercury ≤ 0.1 mg/kg PN-EN 13804:2013-06 + ASA mercury analyser
or PN-EN 13806:2003
Microbiological
TAMC ≤ 5 9 103 CFU/g PN-EN ISO 4833:2004 + AP1:2005
TYMC ≤ 102 CFU/g PN-ISO 7954:1999
Viable Yarrowia lipolytica cells(2) < 10 CFU/g (i.e. limit
of detection)
PN-ISO 7954:1999
Coliforms ≤ 10 CFU/g PN-ISO 4832:2007
Salmonella spp. Absent in 25 g PN-EN ISO 6579:2003
TAMC: total aerobic microbial count; TYMC: total yeast and mould count; CFU: colony forming units; HPLC: high-performance
liquid chromatography; ICP MS: inductively coupled plasma mass spectrometry.
(1): Expressed as selenium.
(2): To be tested immediately after the heat-treatment step. Measures have to be in place to prevent cross-contamination with
viable Yarrowia lipolytica cells during packaging and/or storage of the NF.
6 Commission Implementing Regulation (EU) 2019/760 of 13 May 2019 authorising the placing on the market of Yarrowia
lipolytica yeast biomass as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council and
amending Commission Implementing Regulation (EU) 2017/2470 (Text with EEA relevance.) OJ L 125, 14.5.2019, p. 13–15.
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3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population as proposed by the applicant is the general population from 3 years of age
onwards.
3.7.2. Proposed uses and use levels
Following a request for clariﬁcation on the proposed uses, the applicant stated that the NF is
proposed to be used in food supplements only (in the form of soft or hard capsules, tablets or loose
powder).
The maximum doses of the NF proposed by the applicant are 0.2 g per day for children from 3 to
9 years of age and 1 g per day thereafter (i.e. for adolescents and adults).
3.8. Absorption, distribution, metabolism and excretion (ADME)
No ADME data have been provided for the NF.
3.9. Nutritional information
In its opinion on the safety of Y. lipolytica yeast biomass, the Panel concluded that taking into
account the composition and the proposed conditions of use, the consumption of Y. lipolytica yeast
biomass is not nutritionally disadvantageous (EFSA NDA Panel, 2019). This conclusion was based on
the nutritional analysis of Y. lipolytica biomass (which comprised information on the protein content,
amino acid composition, carbohydrates, ﬁbre, fatty acids, vitamins and minerals) and the proposed
conditions of use (i.e. up to 3 g/day for children from 3 to 9 years of age and up to 6 g/day
thereafter) (EFSA NDA Panel, 2019).
For the NF subject to the current assessment, i.e. Se-enriched Y. lipolytica, the applicant proposed
maximum intakes of 0.2 g/day for children from 3 to 9 years of age and 1 g/day for adolescents (10–
17 years) and adults.
The applicant was informed that when taking into account the intake of selenium via the
background diet (EFSA NDA Panel, 2014), the consumption of the NF at the proposed use levels would
lead to cumulative selenium intakes exceeding the Tolerable Upper Intake Levels (UL) for selenium as
set by the Scientiﬁc Committee on Food (SCF, 2000). Therefore, the applicant was requested to
reconsider and revise the proposed conditions of use. In reply, the applicant lowered the maximum
speciﬁed total selenium concentration in the NF from 240 lg/g to 200 lg/g.
Previously performed intake assessments (EFSA NDA Panel, 2014) indicated average dietary
selenium intakes from 20.6 to 45.9 lg/day for children aged 3–9 years, from 33.9 to 60.3 lg/day for
adolescents (10–17 years) and from 31.0 to 65.6 lg/day for adults. High intakes (at the 95th
percentile) ranged from 31.3 to 71.5 lg/day for children aged 3–9 years, from 55.9 to 95.5 lg/day for
adolescents and from 49.6 to 113.0 lg/day for adults. The Panel recommended that the results should
be considered indicative and be interpreted with caution, due to uncertainties on how accurately the
information contained in the nutrient composition database reﬂects the variability in selenium
concentrations in foods (EFSA NDA Panel, 2014).
Considering a maximum selenium concentration in the NF of 200 lg Se/g, the high (i.e. P95)
dietary selenium intakes (as estimated in 2014) were used for the intake scenario for the various
target population groups as proposed by the applicant (Table 5).
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The Panel notes that for all population groups, except for children from 7-9 years, the intake levels
of the NF as proposed by the applicant would, in combination with a background diet high in selenium,
lead to total selenium intakes which exceed the UL set for selenium (SCF, 2000).
The Panel also notes that in some countries in the EU high dietary selenium intakes in 3 years old
children are already exceeding the UL for selenium (i.e. 60 lg/d) set for this age group.
In the diet selenium is mainly present in organic compounds, as L-selenomethionine and
L-selenocysteine, with lower amounts in inorganic compounds, as selenate and selenite (EFSA NDA
Panel, 2014). The Panel considers that the selenium compounds provided by the NF are the same as
those present in other dietary sources.
3.10. Toxicological information
The applicant provided one acute oral toxicity study (Institute of Industrial Organic Chemistry/
Branch Pszczyna, 2014) in rats, according to OECD TG 420. In the study, ﬁve female Wistar rats were
given (by gavage) one dose each of 2000 mg/kg body weight (bw) of the NF (corresponding to
330 lg Se/kg bw). No deaths occurred during the 14-day observation period following administration
of the NF. No adverse reactions or changes in movement, behaviour and response to stimuli, skin and
fur condition, eye and eyelid status, and respiratory, digestive, urinary and reproductive systems were
observed. No pathological changes were seen in the animals during the macroscopic examination of
tissues at the end of the study.
The applicant did not submit any further relevant toxicological studies performed with the NF.
No human studies with the NF were provided.
The Panel considers that given the QPS status for production purposes of Y. lipolytica (see
Section 3.2), the compositional data of the NF and the fact that the production process of the NF
does not raise safety concerns, no toxicological studies are needed for the safety assessment of the
NF.
The UL for selenium of 300 lg/day for adults, as adopted by the SCF in 2000 was based on a no
observed adverse effect level (NOAEL) of 850 lg/day for clinical selenosis in subjects exposed on a
lifetime basis to selenium in their diet and drinking water. An uncertainty factor of 3 was applied,
supported by three studies reporting no adverse effects for selenium intake between about 200 and
500 lg/day. On the basis of reference body weights, the UL from the adults was extrapolated to
children (SCF, 2000).
The Panel notes that, in recent years, a large amount of new data relevant for the assessment of
the safety of selenium intake, including large population-based randomised controlled trials (RCTs),
has become available. The results of these trials may challenge the UL for selenium as established in
2000, suggesting that the safe range intake could be narrower, in line with the indication of possible
adverse effects of high selenoprotein levels (Stranges et al., 2007; Lippman et al., 2009;
Steinbrenner, 2013; Hatﬁeld et al., 2014; Winther et al., 2015; Mita et al., 2017; Brigelius-Flohe and
Arner, 2018; Kikuchi et al., 2018; Peters et al., 2018; Rayman et al., 2018; Vinceti et al., 2018a,b;
Kim et al., 2019). The Panel considers that newly emerging data warrant a reassessment of the UL
for selenium.
Table 5: Intake scenario for selenium, based on P95 dietary Se-intakes and the use of the NF as
proposed by the applicant considering a maximum selenium concentration of 200 lg Se/g
in the NF
Population
Age
(years)
Proposed
use of the NF
Se from the
NF (lg/d)
High (P95) dietary
Se-intake (lg/d)
Combined
Se-intake (lg/d)
UL(1) for
Se (lg/d)
Children 3
0.2 g/d 40 71.5 111.5
60
4–6 90
7–9 130
Adolescents 10
1 g/d 200 95.5 295.5
130
11–14 200
15–17 250
Adults ≥ 18 113.0 313.0 300
NF: novel food.
(1): Tolerable Upper Intake Level (SCF, 2000).
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3.11. Allergenicity
In its previous opinion on Y. lipolytica biomass, the Panel considered that the risk of allergic
reactions to the biomass of Y. lipolytica is low (EFSA NDA Panel, 2019).
The Panel considers that the conclusion from the previous opinion also applies to the NF under
assessment, i.e. selenium-enriched Y. lipolytica biomass.
4. Discussion
The NF is the selenium-enriched biomass of the yeast Y. lipolytica, which is produced by
fermentation in the presence of sodium selenite.
The NF is proposed by the applicant to be used in food supplements for the general population
from 3 years of age onwards. The maximum doses of the NF proposed by the applicant are 0.2 g per
day for children from 3 to 9 years of age and 1 g per day thereafter (i.e. adolescents and adults), with
a maximum total selenium concentration in the NF of 200 lg Se/g.
Y. lipolytica has been attributed QPS status for production purposes, including food and feed
products based on biomass of the yeast. The qualiﬁcation ‘for production purposes’ requires that there
are no viable Y. lipolytica cells in the ﬁnal product.
In 2019, the Panel has already favourably assessed the safety of Y. lipolytica biomass at levels up
to 3 g/day for children from 3 to 9 years of age and up to 6 g/day thereafter.
Apart from one acute oral toxicity study, no relevant toxicological information was provided for the
NF. The Panel considers that given the QPS status of the yeast, the compositional data of the NF and
the fact that the production process of the NF does not raise safety concerns, no toxicological studies
are needed for the safety assessment of the NF.
In the diet, selenium is mainly present in organic compounds, as L-selenomethionine and
L-selenocysteine, with lower amounts in inorganic compounds. The Panel considers that the selenium
compounds provided by the NF are the same as those present in other dietary sources and that they
are, therefore, as safe as those.
The Panel considers that newly emerging data warrant a reassessment of the UL for selenium.
5. Conclusions
The Panel considers that the yeast biomass (i.e. Y. lipolytica) is not of safety concern at the
proposed use levels.
The Panel also considers that the selenium provided by the NF is as safe as selenium from other
dietary sources.
However, the Panel notes that, at the use levels proposed by the applicant, the intake of the NF
could, in combination with a background diet high in selenium, lead to total selenium intakes
exceeding the UL for selenium in all target population groups, except for children from 7 to 9 years.
Furthermore, the Panel considers that newly emerging data warrant a reassessment of the UL for
selenium.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of selenium-enriched biomass from Yarrowia
lipolytica as a novel food. Ref. Nr. Ares(2019)999294, dated 18 February 2019.
2) On 18 February 2019, a valid application on selenium-enriched biomass from Yarrowia
lipolytica, which was submitted by Skotan S.A., was made available to EFSA by the European
Commission through the Commission e-submission portal (NF 2018/0605) and the scientiﬁc
evaluation procedure was initiated.
3) On 3 May 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientiﬁc evaluation was suspended.
4) On 30 August 2019, additional information was provided by the applicant and the scientiﬁc
evaluation was restarted.
5) During its meeting on 18 December 2019, the NDA Panel, having evaluated the data,
adopted a scientiﬁc opinion on the safety of selenium-enriched biomass from Yarrowia
lipolytica as a NF pursuant to Regulation (EU) 2015/2283.
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Abbreviations
Acc accelerated
ADME absorption, distribution, metabolism and excretion
bw body weight
CFU colony forming units
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Points
HPLC high-performance liquid chromatography
ICP MS inductively coupled plasma mass spectrometry
NF novel food
NOAEL no observed adverse effect level
OECD Organisation for Economic Co-operation and Development
QPS qualiﬁed presumption of safety
RCT randomised controlled trial
RH relative humidity
SD standard deviation
Se selenium
TAMC total aerobic microbial count
TYMC total yeast and mould count
UL Tolerable Upper Intake Level
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